Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | HSD11B2 | P80365 | 3/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1108877 | 0.87 | KMT2A (0.43) | OPRM1OPRD1OPRK1HSD11B1NR1I2 | |
| SCHEMBL1108856 | 0.86 | OPRM1 (0.41) | OPRM1OPRD1OPRK1HSD11B1NR1I2 | |
| SCHEMBL1108833 | 0.86 | OPRM1 (0.43) | OPRM1OPRD1OPRK1HSD11B1NR1I2 | |
| SCHEMBL1108837 | 0.84 | OPRM1 (0.40) | OPRM1OPRD1OPRK1HSD11B1NR1I2 | |
| SCHEMBL1108891 | 0.84 | HSD11B1 (0.41) | OPRM1OPRD1OPRK1HSD11B1NR1I2 | |
| SCHEMBL1108868 | 0.84 | OPRM1 (0.40) | OPRM1OPRD1OPRK1HSD11B1NR1I2 | |
| SCHEMBL1108831 | 0.83 | OPRM1 (0.41) | OPRM1OPRD1OPRK1HSD11B1NR1I2 | |
| SCHEMBL1108829 | 0.83 | NOTUM (0.41) | OPRM1OPRD1OPRK1HSD11B1NR1I2 | |
| SCHEMBL1108840 | 0.83 | OPRM1 (0.39) | OPRM1OPRD1OPRK1HSD11B1NR1I2 | |
| SCHEMBL1108839 | 0.83 | HSD11B1 (0.53) | OPRM1OPRD1OPRK1HSD11B1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153631-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153631-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153631-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-7683059-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683059-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683059-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20100062972-A1 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | AMGEN INC. | 2010-03-11 | — | — | US | disclosed |
| US-20100062972-A1 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | AMGEN INC. | 2010-03-11 | — | — | US | disclosed |
| US-20100062972-A1 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | AMGEN INC. | 2010-03-11 | — | — | US | disclosed |
| US-20080249084-A1 | Triazole Compounds and Uses Related Thereto | AMGEN SF LLC | 2008-10-09 | — | — | US | disclosed |
| US-20080249084-A1 | Triazole Compounds and Uses Related Thereto | AMGEN SF LLC | 2008-10-09 | — | — | US | disclosed |
| US-20080249084-A1 | Triazole Compounds and Uses Related Thereto | AMGEN SF LLC | 2008-10-09 | — | — | US | disclosed |
| EP-1680114-A4 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | AMGEN INC (US) | 2008-09-24 | — | — | EP | disclosed |
| EP-1680114-A2 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | Amgen Inc. (US) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005044192-A2 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | AMGEN INC. (US) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100062972-A1 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | HSD11B1, HSD17B1, HSD17B3 | OPRM1 4331/4885OPRD1 3232/4885OPRK1 2618/4885 |
| US-20080249084-A1 | Triazole Compounds and Uses Related Thereto | GPR119, CYP11B2, CYP11B1 | OPRM1 4060/4885OPRD1 3328/4885OPRK1 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.